Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) rose 5.8% during mid-day trading on Wednesday . The stock traded as high as $27.45 and last traded at $27.01, with a volume of 1,576,189 shares. The stock had previously closed at $25.52.

A number of equities analysts have recently weighed in on SRPT shares. Cowen and Company reiterated a “hold” rating on shares of Sarepta Therapeutics in a report on Sunday, April 17th. Jefferies Group reiterated a “hold” rating and issued a $14.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, April 19th. Janney Montgomery Scott started coverage on Sarepta Therapeutics in a report on Wednesday, April 20th. They issued a “neutral” rating and a $19.00 target price on the stock. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a report on Thursday, April 21st. Finally, William Blair downgraded Sarepta Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, April 21st. Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $25.28.

The firm’s market capitalization is $1.22 billion. The firm’s 50 day moving average is $21.31 and its 200-day moving average is $17.75.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same period last year, the business earned ($0.87) earnings per share. Equities analysts anticipate that Sarepta Therapeutics Inc. will post ($5.12) EPS for the current fiscal year.

Several large investors recently added to or reduced their stakes in SRPT. Nationwide Fund Advisors raised its stake in Sarepta Therapeutics by 9.2% in the fourth quarter. Nationwide Fund Advisors now owns 29,223 shares of the company’s stock worth $1,127,000 after buying an additional 2,471 shares during the period. New York State Common Retirement Fund raised its stake in Sarepta Therapeutics by 13.5% in the fourth quarter. New York State Common Retirement Fund now owns 44,700 shares of the company’s stock worth $1,725,000 after buying an additional 5,300 shares during the period. Rhumbline Advisers raised its stake in Sarepta Therapeutics by 16.1% in the fourth quarter. Rhumbline Advisers now owns 47,728 shares of the company’s stock worth $1,841,000 after buying an additional 6,615 shares during the period. Creative Planning raised its stake in Sarepta Therapeutics by 95.7% in the fourth quarter. Creative Planning now owns 52,950 shares of the company’s stock worth $2,043,000 after buying an additional 25,900 shares during the period. Finally, Mutual of America Capital Management LLC raised its stake in Sarepta Therapeutics by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 60,108 shares of the company’s stock worth $2,319,000 after buying an additional 358 shares during the period.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.